NORTHAMPTON, MA / ACCESSWIRE / December 14, 2022 / Quest Diagnostics
"As an Olympian and as a breast cancer survivor, I've learned the importance of following my intuition. If you have a family history of cancer, trust your instincts. Get answers for yourself with hereditary cancer screenings and genetic testing." Chaunté Lowe, 4-time Olympian, patient advocate, and ambassador
Quest Advanced™ Oncology provides testing, advanced services, and expert physician consultation across the entire cancer care continuum. Our advanced testing solutions include molecular, genetic, and genomic testing for hematopathology and solid tumors; esoteric tests requiring higher-order skill, expertise, and service; and precision medicine, including FDA-cleared and/or approved companion diagnostics. In addition, we provide expert physician consultation by more than 650 MDs and PhDs.
Our advanced oncology services also include a variety of educational opportunities. For National Breast Cancer Awareness month in October, Quest was proud to sponsor Sisters Network Inc.-the nation's oldest, largest, and only national Black breast cancer survivorship organization in the US-and its first-ever State of Black Breast Cancer Crisis: a National Townhall Virtual Discussion and Call to Action.
The townhall featured comments from medical experts, elected officials, and key national leaders, including congressional representatives and the Reverend Al Sharpton, with moderation by CNN National Correspondent Athena Jones. Participants heard experts and advocates discuss one of the most critical health issues facing Black women.
The mortality rate for Black women with breast cancer is 41% higher than that of their White counterparts1
Black women under 35 years of age are diagnosed with breast cancer at twice the rate of White women and die at 3 times the rate2
Chaunté Lowe, a 4-time Olympian in track and field, patient advocate, and ambassador, also spoke about this topic with the Oncology team during Quest's annual Accelerate sales conference. Chaunté discussed her experience as a Black breast cancer survivor and worked with the Oncology team throughout the year to raise awareness of the importance of diagnostic testing during a cancer patient's journey. Chaunté, who was never offered hereditary cancer screenings as part of her initial breast cancer treatment, is now receiving genetic counseling through Quest.
1. Richardson LC, Henley SJ, Miller JW, et al. Patterns and trends in age-specific black-white differences in breast cancer incidence and mortality - United States, 1999-2014. MMWR. 2016;65:1093-1098. doi:10. 15585/mmwr.mm6540a1
2. Shavers VL, Harlan LC, Stevens JL. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer. 2003;97(1):134-147. doi:10.1002/cncr.11051
View additional multimedia and more ESG storytelling from Quest Diagnostics on 3blmedia.com.
Contact Info:
Spokesperson: Quest Diagnostics
Website: http://www.questdiagnostics.com
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$163.59 |
Daily Change: | -0.30 -0.18 |
Daily Volume: | 565,007 |
Market Cap: | US$18.260B |
October 23, 2024 October 22, 2024 October 15, 2024 September 18, 2024 August 26, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB